phytanoyl-CoA 2-hydroxylase interacting protein likeGenealiases: []
Q-omics provides the consensus-scored PHYHIPL profile across patient tissues and cancer cell-line models. PHYHIPL expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, PHYHIPL is differentially expressed in 12, with the highest sampling consensus in KICH. Additionally, PHYHIPL protein abundance shows 18,351 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, KICH, and GBM as cancer lineages where PHYHIPL shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PHYHIPL — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PHYHIPL survival associations across molecular data types. PHYHIPL RNA expression shows survival associations in the most cancer types (25), followed by mutation status (2) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PHYHIPL RNA expression–survival associations across cancer types. High PHYHIPL expression shows unfavorable associations in DLBC and UVM, but favorable associations in KIRC, KIRP, BRCA and LGG. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for PHYHIPL RNA expression.
This table summarizes PHYHIPL tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 3. The strongest signals are observed in KICH for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for PHYHIPL. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PHYHIPL shows lower tumor expression in KICH, THCA, KIRC and BRCA and higher tumor expression in LIHC and LUSC. The KICH box plot shows higher PHYHIPL RNA expression in normal versus tumor tissue (log2 FC = −4.503, t-test p < 0.001).
This table shows molecular features associated with PHYHIPL in patient tissues and cancer cell lines. In patient samples, PHYHIPL shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, PHYHIPL RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in LIVER and LARGE_INTESTINE.
